Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Investment analysts at Edison Inv. Res issued their FY2025 earnings per share estimates for Basilea Pharmaceutica in a report released on Thursday, March 27th. Edison Inv. Res analyst J. Prakash expects that the company will earn $4.76 per share for the year.
Basilea Pharmaceutica Price Performance
BPMUF stock remained flat at $54.00 during trading on Monday. The stock's 50 day moving average is $53.04 and its 200 day moving average is $52.70. The company has a quick ratio of 3.27, a current ratio of 4.10 and a debt-to-equity ratio of 5.70. Basilea Pharmaceutica has a 52 week low of $38.60 and a 52 week high of $54.00.
Basilea Pharmaceutica Company Profile
(
Get Free Report)
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Recommended Stories
Before you consider Basilea Pharmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Basilea Pharmaceutica wasn't on the list.
While Basilea Pharmaceutica currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
